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Background
The ring-substituted amphetamine derivative ( ± )-3,4-
methylendioxymethamphetamine (MDMA; Ecstasy) has
become a widely abused psychoactive drug among young
people. Studies indicate that MDMA produces long-term
alterations of serotonergic parameters in the brain of
rodents and primates, and MDMA was also found to be
neurotoxic in humans. The aim of our work was to char-
acterize the regional differences of the damage in the ter-
minal and cellular areas, and the alterations during
recovery. Serotonin (5-HT) plays a key role in the regula-
tion of sleep, hence we used EEG recordings to measure
functional and morphological effects in parallel during
partial damage and recovery of brain serotonergic neu-
rons by MDMA.
Methods
Our goal was to investigate the effects of a single dose (15
mg/kg) of MDMA on serotonin transporter and several
sleep parameters 7, 21 and 180 days after MDMA admin-
istration in the Dark Agouti rat brain. The expression of 5-
HT mRNA was compared in MDMA-treated and control
animals in the dorsal and median raphe nuclei. The den-
sity of immunostained 5-HT fibers was quantified in sev-
eral brain areas (e.g. cerebral cortex, hippocampus,
hypothalamus and brainstem). Immunohistochemical
measures and some general parameters (e.g. body weight
and food intake) were also determined one year after the
treatment.
Results
Seven and 21 days after MDMA treatment we observed
significant (20-40%) reductions in 5-HT densities. 5-HT
mRNA expressions were significantly elevated 7 days and
decreased 21 days after MDMA treatment in the dorsal
and median raphe nuclei. We also found alterations in
several sleep parameters after drug treatment. Most of the
above effects, except the decrease in hippocampal 5-HT
densities, were transient; they recovered by 180 days after
MDMA administration. One year after MDMA treatment
we found some recovery in the hippocampus, but the 5-
HT density was still significantly lower in CA2 and CA3
regions.
Conclusion
Our results indicate that a single dose of MDMA causes
long-term damage in the terminal regions and also in neu-
ral functions of the serotonergic system. Interestingly,
although the rate of the axonal damage shows little differ-
ences in the regions innervated by ascending axons, the
process and speed of recovery differs markedly.
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